港股九源基因（02566）今日盘中大涨5.63%，引发市场关注。该公司近期公布的2025年中期业绩虽然显示收入和利润有所下降，但仍有亮点表现，似乎获得了投资者的积极反应。
根据公司8月19日发布的中期业绩报告，截至2025年6月30日的6个月期间，九源基因实现收益人民币6.39亿元，同比下降9.05%；母公司股东应占纯利为9017.4万元，同比下降14.4%。尽管整体业绩出现下滑，但公司在骨科领域的表现亮眼，产品销量同比增长超过10%，医院渗透率持续提升。
虽然上半年收入总额小幅下滑，公司表示这主要受内外部因素综合影响。九源基因强调，将围绕全年经营目标，以稳定现有市场和培育增量市场为着力点实施差异化商业政策，争取实现全年业务收入的平稳增长。这一战略似乎获得了投资者的认可，推动股价上涨。分析人士认为，投资者可能看好公司在骨科领域的增长潜力，以及其应对市场挑战的能力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.